![Voyager Therapeutics, Inc. [VYGR] reports annual net loss of $132.3 million](/_next/image?url=https%3A%2F%2F10kinfo-appdata.s3.us-west-2.amazonaws.com%2Fedgar0105%2FCompanyLogos%2FUS%2FVYGR.png&w=3840&q=75)
Voyager Therapeutics, Inc. [VYGR] reports annual net loss of $132.3 million
Company Reports Revenue of $250.0 million
Voyager Therapeutics, Inc. [VYGR] has reported a net loss of $132.3 million for year ended Dec 31, 2023.
The Company said in a filing before the Securities and Exchange Commission that its total revenue for the year was $250.0 million
Based in LEXINGTON, Massachusetts, Voyager Therapeutics, Inc. operates in the MANUFACTURING sector.
In the Consolidated Statements of Operations and Comprehensive Income (Loss) for the period ending December 31, 2023, the company reported collaboration revenue of $250.008 million, a significant increase compared to $40.907 million in the same period in 2022 and $37.415 million in 2021.
Operating expenses for the current period included research and development costs of $92.172 million, higher than the $60.764 million in 2022 and $73.787 million in 2021. General and administrative expenses were $35.822 million, up from $30.980 million last year and $37.246 million in 2021. The total operating expenses for this period amounted to $127.994 million, compared to $91.744 million in 2022 and $111.033 million in 2021.
